SRT1720

Catalog No.S1129

SRT1720 Chemical Structure

Molecular Weight(MW): 506.02

SRT1720 is a selective SIRT1 activator with EC50 of 0.16 μM in a cell-free assay, but is >230-fold less potent for SIRT2 and SIRT3.

Size Price Stock Quantity  
In DMSO USD 238 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • EMBO J 2013 32, 791-804. SRT1720 purchased from Selleck.

    Sirt1 deacetylase activity is essential for IRF9-mediated ischemic injury. The effects of SRT1720 on Sirt1 deacetylase activity in IRF9-KO and IRF9-TG mice, respectively. *p < 0.05 versus DMSO controls. n = 5.

    J Neurosci 2014 34(36), 11897-912. SRT1720 purchased from Selleck.

  • PAI-1 expression in HUVECs treated with drugs as indicated.(D) senescent HUVECs were treated with SRT1720, culturing for 24, 48 hours. PAI-1 mRNA and protein (E) levels were analyzed using real-time RT–PCR and Western blotting, respectively. The RNA and protein levels were normalized to the internal control β-actin. Data are presented as the mean±SEM of three independent experiments. *P < 0.05 vs. corresponding control. **P < 0.01 vs. corresponding control ***P < 0.001 vs. corresponding control.

    Aging Cell 2014 13(5), 890-9. SRT1720 purchased from Selleck.

    C2C12 myoblasts were transfected with si-CON and si-NDUFV1 for 24 h and then further differentiated into myotubes for 4 days in the absence or presence of pyruvate (25 mM), SRT1720 (2 uM), or resveratrol (Resv; 25 uM). Myogenesis was monitored using MyHC immunofluorescence and DAPI.

    J Biol Chem 2014 289(29), 20012-25. SRT1720 purchased from Selleck.

  • J Biol Chem 2012 287, 19304-19314. SRT1720 purchased from Selleck.

Purity & Quality Control

Choose Selective Sirtuin Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description SRT1720 is a selective SIRT1 activator with EC50 of 0.16 μM in a cell-free assay, but is >230-fold less potent for SIRT2 and SIRT3.
Targets
SIRT1 [1]
(Cell-free assay)
0.16 μM(EC50)
In vitro

The maximum activation ratio of SRT1720 versus the closest sirtuin homologues, SIRT2 (EC1.5 = 37 μM) and SIRT3 (EC1.5 > 300 μM) is up to 781%. SRT1720 binds to the SIRT1 enzyme-peptide substrate complex at an allosteric site amino-terminal to the catalytic domain and lower the Michaelis constant for acetylated substrates. SRT1720 could reduce fed glucose levels. Glucose excursion during an intraperitoneal glucose tolerance test is also significantly reduced in the SRT1720 group, and comparable to rosiglitazone, a PPARγ activator that has been used to treat type 2 diabetes. SRT1720 does not have an effect on fasting glucose in chow-fed mice, revealing that pharmacological SIRT1 activation is unlikely to induce hypoglycaemia. SRT1720 significantly reduces the hyperinsulinaemia after 4 weeks, partially normalizing increased insulin levels similar to rosiglitazone treatment. SRT1720 treatment increases mitochondrial capacity by 15% in gastrocnemius muscle as measured by citrate synthase activity. [1] Higher concentrations of SRT1720 (15 μM) induces a modest (10-20%) decrease in normal cell viability. SRT1720 also significantly inhibits VEGF-dependent MM cell migration. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CACs  MXzGeY5kfGmxbjDBd5NigQ>? MU[0xsDPxE1? MnfQN|DDqG2rbh?= M3HTUmROW09? Mmr5bY5lfWOnczDhZ5V1\SCVSWLUNUBi[3SrdnH0bY9vyqB? MmC5NlYzPTRzMES=
MC3T3-E1 NYmwT2dHTnWwY4Tpc44hSXO|YYm= M3Xu[VExKML3TdMg NFTSVXMyKGh? NWXKSIg5emWmdXPld{B1cGViVFfGMe6zNXO2aX31cIF1\WRiVlXHSkBz\WynYYPlJIlvKGSxc3WtJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYNCpC=> NYDRbnhSOjZzM{[5O|g>
MC3T3-E1 MX;GeY5kfGmxbjDBd5NigQ>? Mn;KNVAhyrWPwrC= MmHlNVIhcA>? M4L6OZJm\HWlZYOgeIhmKF[HR1[gcXJPSSCneIDy[ZN{cW:wIHzleoVteyC|dHnteYxifGWmIHL5JHRITi4Qsh?= NX7rbVNvOjZzM{[5O|g>
MC3T3-E1 MWDGeY5kfGmxbjDBd5NigQ>? NXnycGw4OjBizszN NG\rOnYyKGh? NVz3d3gye3WycILld5NmeyC2aHWgWGdHNc7{LXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIIC0OE9xPDJiTVHQJItqdmG|ZTDvdkBUSVCNL1rOTy=> NU\UXIlrOjZzM{[5O|g>
WE-68 NEPaUpZCeG:ydH;zbZMhSXO|YYm= M1jCRVAuOjRizszN NH3LVXMzPCCq MVXpcoR2[2W|IHPlcIwh\GWjdHigbY4h\G:|ZTDk[ZBmdmSnboTsfS=> NFqxSYEzPjB3NUiwOS=>
SK-ES-1 MmLDRZBweHSxc3nzJGF{e2G7 MmnuNE0yOCEQvF2= NXvINI9ROjRiaB?= NU[3bYQ3cW6mdXPld{Bk\WyuIHTlZZRpKGmwIHTvd4Uh\GWyZX7k[Y51dHl? MWqyOlA2PThyNR?=
SK-N-MC  MlzYRZBweHSxc3nzJGF{e2G7 MVewMVIvPSEQvF2= NGqzdlMzPCCq NGLEfVBqdmS3Y3XzJINmdGxiZHXheIghcW5iZH;z[UBl\XCnbnTlcpRtgQ>? M3vpTlI3ODV3OEC1
WE-68 M1rqb2Z2dmO2aX;uJGF{e2G7 M1jFXVIxKM7:TR?= NEf6eoYxNTJ2IHi= Mk\YZYN1cX[jdHXzJINie3Cjc3WgN{84 MnnkNlYxPTV6MEW=
SK-ES-1 NUTrd3hNTnWwY4Tpc44hSXO|YYm= NF3KOZIyOCEQvF2= MYmwMVI1KGh? M3j2PYFkfGm4YYTld{Bk[XOyYYPlJFMwPw>? NXj5eJU3OjZyNUW4NFU>
SK-N-MC  MmjkSpVv[3Srb36gRZN{[Xl? Mnf2N{DPxE1? MoW5NE0zPCCq M3exOYFkfGm4YYTld{Bk[XOyYYPlJFMwPw>? MWmyOlA2PThyNR?=
NRK-49F MWjGeY5kfGmxbjDBd5NigQ>? NYfmZm1COOLCk{NCpO69VQ>? NGfzcGY{PiCq M1\5WYlv[3KnYYPld{BmgHC{ZYPzbY9vKG:oIN8xMXNOSSCjbnSg[oljem:wZXP0bY4h\G:|ZTDk[ZBmdmSnboTsfS=> MU[yOlAzOjByMx?=
NRK-49F NXfWOlRITnWwY4Tpc44hSXO|YYm= MVqw5qCUOsLizszN M2jvdVM3KGh? MY\lcohidmOnczDwbI9{eGixconsZZRqd25ib3[gSWdHWiCjbnSgVGRITlMQstMg MV2yOlAzOjByMx?=
NRK-49F M1;oZWZ2dmO2aX;uJGF{e2G7 MUWw5qCUOsLizszN NFTtO|Y{PiCq MUXlcohidmOnczDTWGFVOyCyaH;zdIhwenmuYYTpc44> NWPHPHNtOjZyMkKwNFM>
RAW264.7 NE\4TXhHfW6ldHnvckBCe3OjeR?= NHu0fYMyKM7:TR?= MV[2JIg> NWPv[3Z[fXC{ZXf1cIF1\XNidHjlJJJm\HWlZXSgV2lTXDFicILveIVqdiCxcjDtVm5CKGyndnXsd{BjgSCqaXfoJIdtfWOxc3W= NGfpNpUzPTd7M{m5OS=>
MCF10A NWW5fppXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWKwMVIxKM7:TR?= MV2yOEBp NWnLS49[emWmdXPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NXG4fm06OjV2MUGzOVY>
MCF-7 NWTqUI05T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DObVAuOjBizszN M{HFfFI1KGh? NHHXfVhz\WS3Y3XzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MmnlNlU1OTF|NU[=
T47D NVHiOYtMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUWwMVIxKM7:TR?= MlXqNlQhcA>? M3zpZZJm\HWlZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NHrUOI8zPTRzMUO1Oi=>
SKBR3 NYjtc4VzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3u4e|AuOjBizszN NVPUN3hzOjRiaB?= M2W1R5Jm\HWlZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NWXiT3IxOjV2MUGzOVY>
MDA-MB-231 NFT1RWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;UOlZJOC1{MDFOwG0> MkS5NlQhcA>? NUXtR4NPemWmdXPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MVSyOVQyOTN3Nh?=
SUM149 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvxNE0zOCEQvF2= Ml3YNlQhcA>? NE\MdWlz\WS3Y3XzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? Mkf0NlU1OTF|NU[=
HS578T MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFeyd4UxNTJyIN88US=> MWmyOEBp MlvOdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NEDjdoszPTRzMUO1Oi=>
BT20 NETnW|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVGwMVIxKM7:TR?= M{nFelI1KGh? MXHy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> MlP3NlU1OTF|NU[=
A459 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4n5NVAuOjBizszN MnjrNlQhcA>? MoXCdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MkLYNlU1OTF|NU[=
HCT116 NEXW[I1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUCwMVIxKM7:TR?= M3nyVFI1KGh? M4XQUpJm\HWlZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MlXGNlU1OTF|NU[=
Neu Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7QVIM5OC1{MDFOwG0> MofqNlQhcA>? M{HDVpJm\HWlZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NGLwZVQzPTRzMUO1Oi=>
MDA-MB-231 NUTwdWNwTnWwY4Tpc44hSXO|YYm= Mn32OUDPxE1? MUC4JIg> M2HlV4lv[3KnYYPld{B1cGViboXtZoVzKG:oIHHjbYRq[yC4ZYPpZ5Vt[XJib4LnZY5mdGyncx?= NX7DToFJOjV2MUGzOVY>
MDA-MB-231 NWjGe2ZiTnWwY4Tpc44hSXO|YYm= MYi1JO69VQ>? NFTTVGQyPiCq NIrZSVFqdmS3Y3XzJIx6e2:|b33hcEBu\W2kcnHu[UBx\XKvZXHibYxqgmG2aX;u MVSyOVQyOTN3Nh?=
MC3T3-E1 NYn4Wox4TnWwY4Tpc44hSXO|YYm= MWixNEDPxE1? NFzRNII3OCCvaX9CpC=> MkTTd5VxeHKnc4Pld{B1cGViRlfGMVIue3SrbYXsZZRm\CCxc4Tlc5Bzd3SnZ3XybY4hemWuZXHz[S=> NWK4d2RQOjV{OUCwPVU>
MC3T3-E1 M4fEd2Z2dmO2aX;uJGF{e2G7 NF\WdXUyOCEQvF2= NYfnclUzPjBibXnuxsA> NUHCeYlz[XS2ZX71ZZRmeyC2aHWgSmdHNTJvaX7keYNm\CCxc4Tlc5Bzd3SnZ3XybY4hdVKQQTDlfJBz\XO|aX;u MorhNlUzQTByOUW=
MC3T3-E1 Mn;PSpVv[3Srb36gRZN{[Xl? NVHufI5POTBizszN NXzIOFBWPjBibXnuxsA> MlrXZZR1\W63YYTld{B1cGViRlfGMVIucW6mdXPl[EBwe3Snb4Dyc5Rm\2W{aX6gcXJPSSCneIDy[ZN{cW:w M2LKbFI2OjlyMEm1
MC3T3-E1 M2Tr[mZ2dmO2aX;uJGF{e2G7 Mo\RNVAh|ryP MnfsOlAhdWmwwrC= NEXEOpl{fXCycnXzd4V{KHSqZTDCUXAuPC2|dHnteYxifGWmIG\FS2YhemWuZXHz[S=> NHnQbJIzPDR|NUS0OC=>
MC3T3-E1 NYHUWJpZTnWwY4Tpc44hSXO|YYm= NFH5UIwyOCEQvF2= NH\keFQ3OCCvaX9CpC=> M4O3c5N2eHC{ZYPz[ZMhfGinIGDHSlLPuS2|dHnteYxifGWmIF;QS{Bz\WynYYPl MlX2NlQ{OzN|M{[=
MC3T3-E1 NHrXbnVHfW6ldHnvckBCe3OjeR?= NIm2UlYyOCEQvF2= M13KNVYxKG2rbtMg NGDOWG1z\WS3Y3XzJJRp\SCSR1[y{tEue3SrbYXsZZRm\CCyaH;zdIhwenmuYYTpc44hd2ZicES0M5A1OiCPQWCgb4lv[XOn NGLSZ5MzPDN|M{OzOi=>
MC3T3-E1 M4DYfWZ2dmO2aX;uJGF{e2G7 NHLVOYMyOCEQvF2= MUO2NEBucW8EoB?= MXrheJRmdnWjdHXzJJRp\SCSR1[y{tEucW6mdXPl[EBxcG:|cHjvdplt[XSrb36gc4Yh[m:2aDDNSWsyNzJiYX7kJHJi\i1z M2\oRlI1OzN|M{O2
RPE NGDDUpNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NVL3cIVKPSEEtV2= NWq4RZRJOSCq NELKZ4lifHSnboXheIV{KE:DzsKtbY5lfWOnZDDk[YNz\WG|ZTDv[kBk\WyuII\pZYJqdGm2eR?= NUK4enFlOjRyM{[5N|g>
9607 MVLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFO5VFkyKM7:TR?= NYLaOmtvOzZiaB?= M1PCd4lv[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[2:vcHHy[YQhf2m2aDDt[YxifG:waX6gZYxwdmV? M4\BSFI{PzJ4OUS5
9607 M{HLeWZ2dmO2aX;uJGF{e2G7 NIDJV4cyKM7:TR?= NXzCTldPOzZiaB?= MWjpcoNz\WG|ZYOgV2lTXDFiYX7kJIRm[3KnYYPl[EBi[2W2eXzheIVlNXB3MzDlfJBz\XO|aX;u M{LkWlI{PzJ4OUS5
RPMI.8226 MkSwR4VtdCCYaXHibYxqfHliQYPzZZk> NWT3eVRUPy9zMDFOwG0> MYqyOEBp Ml\1[IVkemWjc3XzJJZq[WKrbHn0fUBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 MonYNlE6PTB5Mki=
U266 NILjfW9E\WyuIG\pZYJqdGm2eTDBd5NigQ>? MUO3M|ExKM7:TR?= MVSyOEBp MV3k[YNz\WG|ZYOgeoli[mmuaYT5JINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm= NEPHZ2ozOTl3MEeyPC=>
MM.1S MkHFR4VtdCCYaXHibYxqfHliQYPzZZk> MVu3M|ExKM7:TR?= MVKyOEBp Mmnt[IVkemWjc3XzJJZq[WKrbHn0fUBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 MnX5NlE6PTB5Mki=
KMS12 NHS2UGRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NF7mTpo4NzFyIN88US=> NI\KbmMzPCCq MVjk[YNz\WG|ZYOgeoli[mmuaYT5JINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm= NX7UdHZ[OjF7NUC3Nlg>
LR5 Ml;UR4VtdCCYaXHibYxqfHliQYPzZZk> MnTqO{8yOCEQvF2= NIjBeIMzPCCq NVHTWGJx\GWlcnXhd4V{KH[rYXLpcIl1gSClb37j[Y51emG2aX;uJIRmeGWwZHXueIx6 MWmyNVk2ODd{OB?=
MM.1R NILBRplE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MnjmO{8yOCEQvF2= NXLWT5Y2OjRiaB?= NEXTb|Nl\WO{ZXHz[ZMhfmmjYnnsbZR6KGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk> MUSyNVk2ODd{OB?=
Ina6 NFrl[HVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1PMb|cwOTBizszN MnjMNlQhcA>? M2PaXYRm[3KnYYPld{B3cWGkaXzpeJkh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=> Ml[wNlE6PTB5Mki=
RPMI-8226 NUjnUZVWSXCxcITvd4l{KEG|c3H5 NH\kflA4NzFyIN88US=> NGDoeJAzPCCq MorIbY5lfWOnczDhJJNq\26rZnnjZY51KGmwY4LlZZNmKGmwIITo[UBCdm6neHnuJHYsN1CL4pkSxsBieG:ydH;zbZM> M2T1TlIyQTVyN{K4
MM.1R  MV;BdI9xfG:|aYOgRZN{[Xl? MUm3M|ExKM7:TR?= NUG4OJpQOjRiaB?= M1XhbYlv\HWlZYOgZUB{cWewaX\pZ4FvfCCrbnPy[YF{\SCrbjD0bIUhSW6wZYjpckBXMy:SSfMIluKh[XCxcITvd4l{ NGfHclUzOTl3MEeyPC=>
H411EC3 MV\GeY5kfGmxbjDBd5NigQ>? M3zESVUxNzFyMDDuUS=> NHP5OIo3KGh? MWnpcoNz\WG|ZYOgV2lTXDFiYXP0bZZqfHliaX6geIhmKHC{ZYPlcoNmKG:oIGTTRUwhWEWSQ1ugZYN1cX[rdImsJI1TVkFibHX2[Yx{KG:oIGDjb|Eh[W6mIGDnZ|HPuSxiYX7kJIVt\X[jdHnu[{BodHWlb4PlJJBzd2S3Y4Tpc44> M2XPNFIyOjF{MEm2
hepatocytes Ml62SpVv[3Srb36gRZN{[Xl? MWKxNEBvVQ>? M1;6V|YhcA>? MmXBbY5kemWjc3XzJHNKWlRzIHHjeIl3cXS7IHnuJJRp\SCycnXz[Y5k\SCxZjDUV2EtKFCHUFPLJIFkfGm4aYT5MEBuWk6DIHzleoVteyCxZjDQZ4syKGGwZDDQ[4My|rFuIHHu[EBmdGW4YYTpcoch\2y3Y3;z[UBxem:mdXP0bY9v MnPpNlEzOTJyOU[=
hepatocytes NIPSU3ZHfW6ldHnvckBCe3OjeR?= M2DvSlExKG6P MX22JIg> MUnpcoNz\WG|ZYOgTI1o[3MEoHHu[OKhSWOlwrDn[Y5mKGW6cILld5Nqd25? M4D3blIyOjF{MEm2

... Click to View More Cell Line Experimental Data

In vivo In DIO mice SRT1720 mimics several of the effects observed after calorie restriction including improved insulin sensitivity, normalized glucose and insulin levels, and increased mitochondrial capacity. In addition, in diet-induced obese and genetically obese mice, SRT1720 improves insulin sensitivity, lower plasma glucose, and increase mitochondrial capacity. Thus, SRT1720 is a promising new therapeutic agent for treating diseases of ageing such as type 2 diabetes. Consistent with improved glucose tolerance, the glucose infusion rate required to maintain euglycaemia is approximately 35% higher in SRT1720-treated fa/fa rats, and the total glucose disposal rate is increased by approximately 20%. [1] SRT1720 also prevents multiple myeloma tumor growth. SRT1720 increases the cytotoxic activity of bortezomib or dexamethasone. [2]

Protocol

Kinase Assay:[1]
+ Expand

SIRT1 fluorescence polarization assay:

In the SIRT1 FP assay, SIRT1 activity is monitored using a 20 amino acid peptide (Ac-Glu-Glu-Lys(biotin)-Gly-Gln-Ser-Thr-Ser-Ser-His-Ser-Lys(Ac)-Nle-Ser-Thr-Glu-Gly–Lys(MR121 or Tamra)-Glu-Glu-NH2) derived from the sequence of p53. The peptide is N-terminally linked to biotin and C-terminally modified with a fluorescent tag. The reaction for monitoring enzyme activity is a coupled enzyme assay where the first reaction is the deacetylation reaction catalyzed by SIRT1 and the second reaction is cleavage by trypsin at the newly exposed lysine residue. The reaction is stopped and streptavidin is added in order to accentuate the mass differences between substrate and product. The sensitivity of the FP assay allows identification of SRT1720. The fluorescence polarization reaction conditions are as follows: 0.5 μM peptide substrate, 150 μM βNAD+, 0-10 nM SIRT1, 25 mM Tris-acetate pH 8, 137 mM Na-Ac, 2.7 mM K-Ac, 1 mM Mg-Ac, 0.05% Tween-20, 0.1% Pluronic F127, 10 mM CaCl 2, 5 mM DTT, 0.025% BSA, and 0.15 mM nicotinamide. The reaction is incubated at 37 °C and stopped by addition of nicotinamide, and trypsin is added to cleave the deacetylated substrate. This reaction is incubated at 37 °C in the presence of 1 μM streptavidin. Fluorescent polarization is determined at excitation (650 nm) and emission (680 nm) wavelengths.
Cell Research:[2]
+ Expand
  • Cell lines: Human vascular endothelial cells (HUVECs)
  • Concentrations: 5 μM
  • Incubation Time: 2 hours
  • Method: Transwell Insert Assays are utilized to measure migration. In vitro angiogenesis is assessed by Matrigel capillary-like tube structure formation assay. For endothelial tube formation assay, human vascular endothelial cells (HUVECs) are obtained from Clonetics and maintained in endothelial cell growth medium-2 containing 5% FBS. After three passages, HUVEC cell viability is measured with the trypan blue exclusion assay, and <5% of cell death is observed with SRT1720 treatment.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Chase-SCID mice with MM.1S cells
  • Formulation: 20% PEG400/0.5% Tween80/79.5% deionized water
  • Dosages: 200 mg/kg
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 38 mg/mL (75.09 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 506.02
Formula

C25H23N7OS.HCl

CAS No. 1001645-58-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Sirtuin Signaling Pathway Map

Related Sirtuin Products

Tags: buy SRT1720 | SRT1720 supplier | purchase SRT1720 | SRT1720 cost | SRT1720 manufacturer | order SRT1720 | SRT1720 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID